Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
Baptist Health South Florida
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Massachusetts General Hospital
Incyte Corporation
Reveal Pharmaceuticals Inc.
National Cancer Institute (NCI)
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
Dana-Farber Cancer Institute
Miltenyi Biomedicine GmbH
Medical College of Wisconsin
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Radiation Therapy Oncology Group
Celgene
Memorial Sloan Kettering Cancer Center
UNICANCER
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Radiation Therapy Oncology Group
OHSU Knight Cancer Institute
TVAX Biomedical
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
St. Jude Children's Research Hospital
Children's Oncology Group
Rush University Medical Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Wake Forest University Health Sciences
University of South Florida
National Cancer Institute (NCI)
University of California, San Francisco
UNICANCER
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group